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Accepted 30 July 2010AbstractObjective: The present retrospective and controlled comparative study was designed to evaluate the pregnancy rate achieved using a modified, fixed,
multiple-dose 0.125 mg gonadotropin-releasing hormone (GnRH) antagonist protocol with the long GnRH agonist protocol as the control group.
Materials and methods: One hundred and twenty unselected women between 30 and 40 years of age, in their first cycle of IVF/ICSI, with
a baseline follicle-stimulating hormone (FSH) <10 IU and an antral follicle count >3 were assigned into two groups: (1) the study group
received 0.125 mg of cetrorelix daily starting on Day 6 of stimulation; and (2) the control group received leuprolide daily starting in the
mid-luteal phase of the preceding cycle. Both groups were given a flexible dose of recombinant FSH for stimulation. An ongoing pregnancy rate
of more than 12 weeks was the primary outcome measure of the study.
Results: Primary and secondary outcomes were comparable in both groups. A shorter duration of stimulation, a lower dosage of recombinant
FSH consumption and a thinner endometrium on the day of human chorionic gonadotropin administration were all observed in the GnRH
antagonist group.
Conclusion: A dosage of 0.125 mg GnRH antagonist protocol was effective for these unselected patients during IVF/ET.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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A long protocol using a gonadotropin-releasing hormone
(GnRH) agonist suppressing pituitary function to prevent
a premature LH surge has been used commonly to stimulate
ovulation. However, oversuppression of the pituitary function
may result in a higher overall dose of gonadotropin and
a longer duration of stimulation [1], especially for those women
who respond poorly to reproductive treatment. A decade
ago, the role of antagonists in stimulation of ovulation was* Corresponding author. Department of Obstetrics and Gynecology, Chang
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doi:10.1016/j.tjog.2011.10.006evaluated [2]. The advantages of a GnRH antagonist are that (1)
a shorter time is required to prevent the LH surge [3]; (2) there
is a reduced requirement for exogenous gonadotropin; and (3)
there is a shorter duration of stimulation [4]. For these reasons,
many studies have aimed to evaluate the role of antagonists in
stimulation of ovulation for poor responders, i.e., those women
with repeated failures or poor responses in previous ovulation-
stimulation cycles. The results have been encouraging [4e6].
Moreover, the role of GnRH antagonists in normal
responders or in non-selected patients is still under debate
because there was a lower rate of clinical pregnancy and fewer
oocytes were retrieved [7]. The necessity of further studies
aimed at more flexible GnRH antagonist regimens, such as the
timing of initiation and the dosage of the GnRH antagonist,
as well as the timing of the human chorionic gonadotropincs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Fig. 1. Study flow chart and outcomes.
Table 1
Patient demographics.
Antagonist group Agonist group p valuesa
Age (y) 34.6 4.3 33.8 3.5 0.27
Duration of infertility (y) 4.1 3.0 3.2 2.3 0.24
Body mass index (kg/m2) 22.1 3.0 23.6 5.4 0.12
FSH on days 2e3 (IU/L) 7.2 2.7 7.4 2.7 0.76
Antral follicle count 7.6 3.4 8.5 4.1 0.17
Note: values expressed as mean SD.
a Calculated by t test.
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fore, we designed a retrospective comparative study to assess
whether the GnRH antagonist protocol is suitable for unse-
lected patients. The demographics, protocol pattern, laboratory
results and pregnancy outcome were analyzed.
Materials and methods
The study was performed between January 2008 and July
2009. Women between 30 and 40 years of age, in their first
cycle of in vitro fertilization (IVF) or intracytoplasmic semen
injection (ICSI), with a basal follicle-stimulating hormone
(FSH) <10 IU and a total early antral follicle count >3 were
enrolled in this study. Patients were excluded from this study
if: (1) they had undergone oocyte cryopreservation due to
a medical condition; or (2) ICSI was performed for preim-
plantation diagnosis (or exclusion) of inherited disease.
Protocol design
GnRH agonist, 0.5e1 mg/day, (Lupron, Takeda, Osaka,
Japan) was administered subcutaneously in the mid-luteal phase
of the menstrual cycle in the GnRH agonist group. Patients
received recombinant FSH (r-FSH) (Gonal-F, Serono, Interna-
tional, Geneva, Switzerland or Puregon; N.V. Oganon, Oss,
Netherlands) in a variable dosage until the day of hCG admin-
istration after downregulation of the pituitary function, with
a serum E2 level <45 pg/mL. In the GnRH antagonist group,
0.125 mg/day of GnRH antagonist (Cetrotide; Serono Interna-
tional, Geneva, Switzerland) was administered intramuscularly
on Day 6 of stimulation until the day of administration of hCG.
All patients received r-FSH in variable dosages and durations
based on the ultrasound appearance of the follicles and the
serum estradiol (E2) levels during the stimulation of ovulation.
Serial transvaginal ultrasonography was arranged to monitor the
follicular growth and endometrial thickness every 2 to 3 days
after beginning the stimulation cycle. The serum level of E2 was
checked on the day of ultrasonography. When the leading
follicle reached a diameter of 17 mm, 10000 IU hCG (Ovidrel,
Serono International, Geneva, Switzerland) was administrated
to trigger ovulation. Oocyte retrieval was performed 36 hours
later. Retrieved oocytes were graded as mature if a corona
radiata and the first polar body were visible. Oocytes were
inseminated with either IVF or ICSI, according to clinical
needs. No more than four embryos were transferred on Day 3
after oocyte retrieval. A urine pregnancy test was performed 2
weeks after the embryo transfer. For those patients with
a negative pregnancy test result, serum hCG levels were
checked to confirm the result. For those with a positive urine
pregnancy test, an ultrasound scan was carried out 3 weeks later.
Data analysis
Results were presented as the mean standard deviation.
A t test and a c2 test were used to calculate the p value, as
appropriate. A two-sided p value of <0.05 was considered
statistically significant. Data were analyzed using thecommercially available software package SPSS (SPSS, Inc.,
version 14, Chicago, IL, USA).
The primary outcome measures were the ongoing pregnancy
rate. Secondary outcome measures were cycle cancellation
rate, fertilization rate, implantation rate and the incidence of
ovarian hyperstimulation syndrome (OHSS).
Results
Fig. 1 depicts the study flow chart. A total of 55 patients in
the GnRH antagonist protocol and 65 patients in the long
GnRH agonist protocol were enrolled for analysis. The rate of
cancellation of cycles in the GnRH antagonist group was less
than that in the GnRH agonist group, but the data did not
achieve statistical significance (0.04 in the antagonist group
vs. 0.11 in the agonist group, p¼ 0.14). Fifty-one patients in
the antagonist group and 56 patients in the agonist group
underwent embryo transfer.
Table 1 shows the demographic characteristics of both
groups. All were on their first cycle of IVF-ET cycle. The
patient’s age, baseline FSH level, early antral follicle count,
duration of infertility and body mass index were similar in
both groups. Infertility causes were mainly combined factors
(22%), tubal factors (25%) and male factors (21%) in the
antagonist group, and male factors (43%) and tubal factors
(24%) in the agonist group.
Table 2 shows stimulation and cycle outcome. The average
duration of r-FSH stimulation in the antagonist group was
Table 2
Stimulation and cycle outcomes.
Antagonist group Agonist group p valuesa
Duration of stimulation (d) 8.5 1.3 9.0 1.7 0.03
Total FSH dosage (IU) 1697.3 547.4 1922.8 561 0.03
Endometrial thickness (cm)
at hCG day
1.0 0.2 1.1 0.2 0.02
E2 (pg/mL) at hCG day 1688.7 1030.1 1929.0 1248.1 0.28
Note: values expressed as mean SD.
a Calculated by t test.
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average total r-FSH dosage was less (1697.3 547.4 IU vs.
1922 561.0 IU, p¼ 0.03), and the endometrium on hCG day
was thinner (1.0 0.2 cm vs. 1.1 0.2 cm, p¼ 0.02) than that
of the agonist group. The serum E2 level on the day of hCG
administration was lower in the antagonist group, but the
difference did not achieve statistical significance.
Table 3 shows the laboratory and pregnancy outcomes. In
the antagonist group, the mean number of retrieved oocytes
(10 6.5 vs.12.6 8.2, p¼ 0.08) and the mean number of
mature oocytes (7.8 4.8 vs. 9.9 6.5, p¼ 0.06) were not
significantly less than in the agonist group. The fertilization
rate in both groups was similar (49% in the antagonist group
vs. 51% in the agonist group, p¼ 0.69). The mean number of
transferred embryos was 2.8 (0.9) in the antagonist group
and 3.0 (1.0) in the agonist group ( p¼ 0.38). The implan-
tation rate in the antagonist group was 21% as compared to
23% in the agonist group ( p¼ 0.69). The overall pregnancy
rate per cycle (42% vs. 40%), the pregnancy rate per oocyte
retrieval (43% vs. 45%), the pregnancy rate per embryo
transfer (45% vs. 46%) and the ongoing pregnancy rate per
embryo transfer (39% vs. 36%) are shown in Table 3. There
was no statistically significant difference between the two
groups in these outcomes. The incidence of OHSS was 0.04 in
the antagonist group and 0.05 in the agonist group, and there
was no statistically significant difference ( p¼ 0.79).
Discussion
To the best of our knowledge, our study was the first to
evaluate the clinical efficacy of 0.125 mg GnRH antagonist in
a modified, fixed, multiple-dose protocol for an unselectiveTable 3






No. of oocytes retrieved 10.0 6.5 12.6 8.2 0.08
No. of mature oocytes 7.8 4.8 9.9 6.5 0.06
Fertilization rate 49% 51% 0.69
No. of transferred embryos 2.8 0.9 3.0 1.0 0.38
Implantation rate 0.21 0.23 0.69
Pregnancy rate per oocyte retrieval 43% 45% 0.88
Pregnancy rate per embryo transfer 45% 46% 0.89
Ongoing pregnancy rate per
embryo transfer
39% 36% 0.71
Note: values expressed as mean SD.
a Calculated by t test or c2 test.population. The results showed that this protocol had
comparable pregnancy rates to the GnRH agonist protocol.
The pharmacodynamic effect of a 0.125 mg GnRH antag-
onist was shown to be similar to that of a 0.25 mg dose, but the
serum hormone levels were suppressed more profoundly in the
latter group [8]. Doses of GnRH antagonist that were too low
resulted in an increased incidence of premature LH surge [9].
Consequently, the recommended dose of GnRH was at least
0.25 mg. Recently there was a report addressing the use of
0.125 mg GnRH antagonist in a controlled ovarian hyper-
stimulation/intrauterine insemination, and the clinical results
were satisfactory [10]. In this study we also tried to evaluate
the clinical effect of 0.125 mg GnRH antagonist, and our
results showed a compatible retrieved oocyte number and
matured oocyte number between the 0.125 mg GnRH antag-
onist group and the GnRH agonist group, and the pregnancy
rates were also comparable in both groups. In our study, we
could not exclude the phenomenon of premature LH surge,
since we did not monitor the serum LH and progesterone
levels during the ovulation stimulation and on hCG day. Based
on the fact that an adequate number of matured oocytes were
retrieved in the GnRH antagonist group and the morphological
observation of the oocytes through microscopy, we did not find
evidence showing either premature luteinization or the
premature rupture of follicles in our patients.
Possible explanations for these results could be that (1) our
study population was all Asian women with thin frames (BMI:
22.1); and (2) the hCG was administered earlier, when the
dominant follicle reached 1.7 cm in diameter, before the
clinical rise of the LH. In addition, the body weight, rather
than the body mass index (BMI), was the most common
parameter for determining the dosage in routine pharmacoki-
netic studies. Patients with the same BMI but different body
heights may have very different body weights. The significant
body weight difference between Asian and Western women
explains our reason for choosing the 0.125 mg daily dose of
cetrorelix in this study. We suggest that a 0.125 mg daily dose
of cetrorelix could achieve comparable treatment outcomes
without inducing premature luteinization in patients with body
weights less than 56 kg, or with a BMI less than 22 kg/m2.
Further randomized prospective study to evaluate the efficacy
of a 0.125 mg GnRH antagonist is absolutely necessary to
establish the clinical value of this protocol.
Our study showed two clinical advantages of the GnRH
antagonist protocol: (1) the stimulation duration was shorter;
and (2) there was less usage of r-FSH. Current consensus is
that a higher dose leads to the retrieval of more oocytes but
similar pregnancy rates in standard patients (younger than 40
years of age, having two ovaries, a normal menstrual cycle and
a normal basal FSH level) [11]. The recommended dose of
FSH was 100 to 250 IU/day for the standard population in the
agonist protocol and 150 IU/day or 200 IU/day in the GnRH
antagonist cycles [12]. An increased dose did not compensate
for the age-related decline in ovarian function. Based on this
reasoning, both the antagonist group and the agonist group
were treated with the recommended dose of r-FSH in our study
and showed comparable outcome. Shorter stimulation duration
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but also decreased their economic burden. The average cost of
medication during ovulation stimulation in patients accepting
the GnRH antagonist protocol was 625 USD as compared to
750 USD in the agonist group. More specific analysis should
be done in the future on the cost effectiveness of this modified,
fixed, multiple-dose 0.125 mg GnRH antagonist protocol.
Endometrial thickness was thinner on hCG day during the
GnRH antagonist cycle in our study. Characteristics of the
endometrium measurable by ultrasound, such as endometrial
thickness, played a role in implantation, and had a strong
negative value in setting some minimal criteria in the artificial
reproductive technique protocol [13]. An endometrium thick-
ness of less than 0.8 cm was believed to relate to a low rate of
pregnancy. The etiology of decreased endometrial thickness in
the antagonist protocol was unclear. We could not prove that
decreased endometrial thickness had any effect on the preg-
nancy rate, but caution should be exercised in the use of
a GnRH antagonist in those patients with a poor endometrial
condition, history of repeated induced abortion, or scant
menstrual flow.
A lower E2 serum level on hCG day in the GnRH antag-
onist protocol has been described in previous studies [14e16].
Endometrial receptivity is a crucial factor in determining the
success of IVF. A high estradiol concentration on the day of
hCG administration is detrimental to uterine receptivity [17].
Excessively high estradiol concentration has been associated
with the dyssynchrony of endometrial glands and stroma,
representing a suboptimal environment for implantation [18].
In vitro study has also demonstrated that a high level of
estradiol itself has a direct toxic effect on the embryo by
affecting the cleavage stage [19]. Therefore, we might assume
that a lower E2 level may contribute to a better treatment
outcome using the antagonist protocol. In our study, however,
the E2 level on hCG day in the GnRH antagonist group was
lower than in the agonist group, but this difference did not
reach statistical significance. The limited number of cases and
the standard r-FSH dosage for the unselective general pop-
ulation in our study were two key factors in explaining the
difference. In addition, our study design was retrospective,
rather than prospective and randomized. Both of these factors
affected the strength of this study.
In conclusion, the 0.125 mg GnRH antagonist modified,
flexible, multiple-dose protocol had a pregnancy rate compa-
rable to that of the GnRH agonist group in our unselected
population. This dose reduced the consumption of r-FSH,
shortened the duration of treatment and proved to be a good
protocol for an unselected population aged between 30 and 40
years at their first IVF-ET cycle. Adverse effects on the
endometrium should be considered when treating the subfertile
patient with a possible unfavorable endometrial condition.
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